Catalyst Biosciences (NASDAQ: CBIO) and Horizon Therapeutics (NASDAQ:HPTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Catalyst Biosciences and Horizon Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Biosciences 0 0 2 0 3.00
Horizon Therapeutics 0 0 0 0 N/A

Catalyst Biosciences currently has a consensus price target of $10.50, indicating a potential upside of 110.84%. Given Catalyst Biosciences’ higher probable upside, research analysts plainly believe Catalyst Biosciences is more favorable than Horizon Therapeutics.

Earnings and Valuation

This table compares Catalyst Biosciences and Horizon Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Catalyst Biosciences $561,999.00 38.19 -$19.79 million ($17.78) -0.28
Horizon Therapeutics N/A N/A N/A N/A N/A

Horizon Therapeutics has higher revenue, but lower earnings than Catalyst Biosciences.


This table compares Catalyst Biosciences and Horizon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalyst Biosciences -3,127.92% -92.61% -46.69%
Horizon Therapeutics 23.13% 21.30% 15.42%

Insider & Institutional Ownership

29.2% of Catalyst Biosciences shares are held by institutional investors. 5.0% of Catalyst Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


Catalyst Biosciences beats Horizon Therapeutics on 5 of the 8 factors compared between the two stocks.

About Catalyst Biosciences

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

About Horizon Therapeutics

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with's FREE daily email newsletter.